Lead Sponsor

Angde Biotech Pharmaceutical Co., Ltd.

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

•1. prescriptions explicitly given to the injection of Baijieyi;
•2. confirmed by histopathological or cytological examination of malignant tumors and chemotherapy;
•3. treatment: platelet count had reached below 75×10\^9/L after the treatment of chemotherapy and before using Baijieyi; prevention: patients with chemotherapy at the beginning of the preventive administration of BaiJieyi, and chemotherapy is same with previous cycle;
•4. male or female, aged 18-85 years;
•5. The main research information required is complete.

•1. using other platelets of chemicals or biological products in the in the chemotherapy cycle used Baijieyi;
•2. using drugs which can cause thrombocytopenia in the in the chemotherapy cycle used Baijieyi;
•3. bone marrow dysfunction or bone marrow involvement;
•4. There are other causes of thrombocytopenia, such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenic purpura, and hypersplenism, in the course of the use of Baijieyi.

Related studies

NCT07492693 · Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors

NCT07063225 · Chemotherapy-induced Thrombocytopenia, Romiplostim N01

NCT05236582 · Chemotherapy-induced Thrombocytopenia, Herombopag

NCT05864014 · Chemotherapy-Induced Thrombocytopenia

NCT07647029 · Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)

A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor